Sequential C–H Arylation and Enantioselective Hydrogenation Enables Ideal Asymmetric Entry to the Indenopiperidine Core of an 11β-HSD-1 Inhibitor
作者:Xudong Wei、Bo Qu、Xingzhong Zeng、Jolaine Savoie、Keith R. Fandrick、Jean-Nicolas Desrosiers、Sergei Tcyrulnikov、Maurice A. Marsini、Frederic G. Buono、Zhibin Li、Bing-Shiou Yang、Wenjun Tang、Nizar Haddad、Osvaldo Gutierrez、Jun Wang、Heewon Lee、Shengli Ma、Scot Campbell、Jon C. Lorenz、Matthias Eckhardt、Frank Himmelsbach、Stefan Peters、Nitinchandra D. Patel、Zhulin Tan、Nathan K. Yee、Jinhua J. Song、Frank Roschangar、Marisa C. Kozlowski、Chris H. Senanayake
DOI:10.1021/jacs.6b09764
日期:2016.11.30
A concise asymmetric synthesis of an 11β-HSD-1 inhibitor has been achieved using inexpensive starting materials with excellent step-economy at low catalyst loadings. The catalytic enantioselective total synthesis of 1 was accomplished in 7 steps and 38% overall yield aided by the development of an innovative, sequential strategy involving Pd-catalyzed pyridinium C-H arylation and Ir-catalyzed asymmetric
11β-HSD-1 抑制剂的简洁不对称合成已经使用廉价的起始材料在低催化剂负载下具有出色的步进经济性。1 的催化对映选择性全合成分 7 步完成,总产率为 38%,这得益于创新的顺序策略的开发,该策略涉及 Pd 催化的吡啶鎓 CH 芳基化和 Ir 催化的所得稠合三环茚并吡啶盐的不对称氢化。使用具有 1000 ppm [Ir(COD)Cl]2 的独特 P,N-配体 (MeO-BoQPhos)。